Last reviewed · How we verify
Dehydroepiandrosterone — Competitive Intelligence Brief
marketed
Corticosteroid-binding globulin, Beta-glucuronidase, Glucose-6-phosphate 1-dehydrogenase
Immunology
Small molecule
Live · refreshed every 30 min
Target snapshot
Dehydroepiandrosterone (Dehydroepiandrosterone) — National Institute of Dental and Craniofacial Research (NIDCR).
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dehydroepiandrosterone TARGET | Dehydroepiandrosterone | National Institute of Dental and Craniofacial Research (NIDCR) | marketed | Corticosteroid-binding globulin, Beta-glucuronidase, Glucose-6-phosphate 1-dehydrogenase | ||
| Intrarosa | Intrarosa | Center for Vulvovaginal Disorders | marketed | Corticosteroid-binding globulin, Beta-glucuronidase, Glucose-6-phosphate 1-dehydrogenase |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dehydroepiandrosterone CI watch — RSS
- Dehydroepiandrosterone CI watch — Atom
- Dehydroepiandrosterone CI watch — JSON
- Dehydroepiandrosterone alone — RSS
Cite this brief
Drug Landscape (2026). Dehydroepiandrosterone — Competitive Intelligence Brief. https://druglandscape.com/ci/dehydroepiandrosterone. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab